Talis Biomedical (NASDAQ:TLIS – Get Rating) was downgraded by analysts at BTIG Research from a “neutral” rating to a “sell” rating in a research report issued to clients and investors on Friday, The Fly reports.
TLIS has been the subject of several other reports. Bank of America decreased their price objective on shares of Talis Biomedical from $3.00 to $1.50 and set an “underperform” rating for the company in a report on Wednesday, March 16th. Zacks Investment Research upgraded shares of Talis Biomedical from a “sell” rating to a “hold” rating in a report on Thursday, March 10th. Three research analysts have rated the stock with a sell rating and two have issued a hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Sell” and a consensus target price of $5.83.
NASDAQ TLIS traded down $0.03 during trading on Friday, hitting $1.52. 97,337 shares of the company traded hands, compared to its average volume of 137,419. Talis Biomedical has a 12 month low of $0.96 and a 12 month high of $16.18. The business’s fifty day simple moving average is $2.30.
Talis Biomedical (NASDAQ:TLIS – Get Rating) last issued its quarterly earnings data on Tuesday, March 15th. The company reported ($1.26) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.28) by $0.02. Talis Biomedical had a negative return on equity of 67.21% and a negative net margin of 2,343.90%. On average, analysts forecast that Talis Biomedical will post -3.35 earnings per share for the current fiscal year.
A number of hedge funds have recently made changes to their positions in TLIS. Wells Fargo & Company MN acquired a new position in Talis Biomedical during the 4th quarter valued at $32,000. Deutsche Bank AG increased its stake in Talis Biomedical by 85.9% during the third quarter. Deutsche Bank AG now owns 15,007 shares of the company’s stock valued at $94,000 after acquiring an additional 6,935 shares during the period. Personal CFO Solutions LLC acquired a new position in Talis Biomedical in the 3rd quarter valued at approximately $106,000. Millennium Management LLC bought a new stake in shares of Talis Biomedical in the 2nd quarter worth approximately $157,000. Finally, Morgan Stanley acquired a new stake in shares of Talis Biomedical during the 1st quarter worth approximately $222,000. 72.38% of the stock is currently owned by institutional investors and hedge funds.
About Talis Biomedical (Get Rating)
Talis Biomedical Corporation operates as a molecular diagnostic company. It is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. The company is also developing Talis One assay kits for respiratory infections, infections related to women’s health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B plus SARS-CoV-2.
Want More Great Investing Ideas?
Receive News & Ratings for Talis Biomedical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Talis Biomedical and related companies with MarketBeat.com’s FREE daily email newsletter.